-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Reiterates Outperform on Xeris Biopharma Holdings, Raises Price Target to $21

Benzinga·11/06/2026 17:33:50
Listen to the news
Oppenheimer analyst Leland Gershell reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price target from $18 to $21.